Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease

This phase II trial studies how well mezigdomide/carfilzomib/dexamethasone (MeziKD) works in treating patients with multiple myeloma (MM) that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory) and have tumors from myeloma cells outside the bone marrow in the soft tissues or organs of the body (extramedullary disease \[EMD\]). Mezigdomide blocks important processes in myeloma cells and may lead to modulation of the immune system, including activation of T-lymphocytes, and downregulation of the activity of other proteins, some of which play

Trial Details

NCT ID
NCT06627751
Phase
PHASE2
Sponsor
Roswell Park Cancer Institute
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Mezigdomide
  • Carfilzomib
  • Dexamethasone
  • Echocardiography
  • Positron Emission Tomography
  • Computed Tomography
Locations (sample)
  • Buffalo, New York, United States|42.88645,-78.87837

Key Eligibility Criteria

  • Age ≥ 18 years of age
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2
  • RRMM patients with one or more prior lines of therapy with at least one ES or PS lesion that is accessible to a biopsy. Accessibility will be asses…
  • Measurable disease meeting at least one of the following:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →